Related Experiment Video
Updated: Aug 6, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Mechanisms underlying renoprotection during renin-angiotensin system blockade
M W Taal1, G M Chertow, H G Rennke
1Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. mtaal@rics.bwh.harvard.edu
Abstract:
Potential determinants of chronic renal disease (CRD) progression were studied in male Munich-Wistar rats subjected to 5/6 nephrectomy and treated with candesartan (Csn; n = 30) or enalapril (Ena; n = 27) from 5 wk postsurgery. Despite control of systolic blood pressure (SBP; 24 wk: Csn = 143 +/- 9; Ena = 148 +/- 8 mmHg), urinary protein excretion rates (U(pr)V) increased over 24 wk (Csn = 92 +/- 10; Ena = 99 +/- 8mg/day). Glomerulosclerosis scores (GS) at 24 wk were similar for Csn (42 +/- 7%) vs. Ena (42 +/- 4%), values close to those of untreated controls at 12 wk (43 +/- 4%). At 24 wk, SBP and UprV correlated strongly with GS, together accounting for 72% of the variance in GS. Renal cortex mRNA levels (determined by competitive RT-PCR) for transforming growth factor (TGF)-beta1 and monocyte chemoattractant protein (MCP)-1 were elevated in Csn and Ena at 12 wk and remained higher at 24 wk vs. sham. Strong correlations were evident among TGF-beta1, MCP-1, and interleukin-1beta and renal injury at 24 wk. Cns and Ena are thus equally effective renoprotective agents in this model. During renin-angiotensin system inhibition, renoprotection is dependent on control of both SBP and UprV. Incomplete suppression of renal cytokine gene expression may also contribute to CRD progression.
Insights
Both candesartan and enalapril equally protect kidneys in rats with chronic renal disease (CRD). Effective renoprotection requires controlling systolic blood pressure and urinary protein excretion.
Area of Science:
- Nephrology
- Pharmacology
Background:
- Chronic renal disease (CRD) progression is a significant health concern.
- Understanding the determinants of CRD progression is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the renoprotective effects of candesartan (Csn) and enalapril (Ena) in a rat model of CRD.
- To identify potential determinants of CRD progression during renin-angiotensin system inhibition.
Main Methods:
- Male Munich-Wistar rats underwent 5/6 nephrectomy and were treated with Csn or Ena.
- Systolic blood pressure (SBP), urinary protein excretion (UprV), and glomerulosclerosis scores (GS) were measured.
- Renal cortex mRNA levels for TGF-beta1 and MCP-1 were determined using RT-PCR.
Main Results:
- Both Csn and Ena controlled SBP but UprV increased over 24 weeks.
- GS scores were similar between Csn and Ena groups and correlated strongly with SBP and UprV.
- Elevated renal TGF-beta1 and MCP-1 mRNA levels correlated with renal injury.
Conclusions:
- Csn and Ena are equally effective renoprotective agents in this CRD model.
- Renoprotection during renin-angiotensin system inhibition depends on controlling both SBP and UprV.
- Incomplete suppression of renal cytokine gene expression may contribute to CRD progression.
Related Concept Videos
Hormonal Regulation
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension II: Pathophysiology

